What's Backing Abbott's Established Pharmaceuticals Division Growth

ABT's EPD growth is fueled by emerging-market strength, broad branded generics and healthcare demand, with biosimilars adding opportunities.

Zacks Investment Research • 18 hours ago

Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis

"We Give Blood" brings together all 18 Big Ten® schools in a competition to drive the most blood donations and win $1 million from global healthcare company Abbott For only the second time in its history, the American Red Cross has declared a national blood crisis after donations dropped to a four-year summer low, threatening the availability of lifesaving blood for patients across the country Abbott and the Big Ten urge people to donate blood now and will count those early donations toward the competition, which officially kicks off Aug. 26 Anyone can donate blood anywhere in the U.S. between Aug. 12-Dec. 4 and log their donation starting Aug. 26 for a Big Ten school at BigTen.org/Abbott or by texting GIVEBLOOD to 222688 (ABBOTT) and select an exclusive, limited-edition T-shirt* while supplies last The movement aims to fuel a new generation of blood donors at a time when 2.5 million donations — nearly a quarter of all donations — come from people over the age of 65 ABBOTT PARK, Ill. and ROSEMONT, Ill.

PRNewsWire • Aug 12, 2026

Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI

Multi-year collaboration combines ongoing glucose insights from Abbott's Lingo biowearable with Google Health's technology to create a more comprehensive view of personal health Partnership includes a large-scale research study to better inform artificial intelligence (AI) coaching available in the Google Health app and future Lingo product features Lingo, Abbott's over-the-counter continuous glucose monitor (CGM), helps people understand the impact of nutrition, activity, sleep and stress on their glucose so they can make meaningful lifestyle changes ABBOTT PARK, Ill., Aug. 11, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a first-of-its-kind partnership with Google Health to redefine how people understand and manage their health.

PRNewsWire • Aug 11, 2026

Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom?

Abbott's Medical Devices growth, EPD momentum and improving Nutrition support its outlook, but China risks, costs and valuation warrant caution.

Zacks Investment Research • Aug 10, 2026

Here's How ABT Broadens Diagnostics Growth Base With Oncology Expansion

Abbott broadens Diagnostics growth with Exact Sciences, as Cancer Diagnostics gains and resilient routine testing offset respiratory weakness.

Zacks Investment Research • Aug 7, 2026

AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie relies on a high-margin biopharmaceutical portfolio and significant free cash flow to drive shareholder value. Abbott Laboratories leverages a highly diversified business model spanning medical devices, diagnostics, and nutritional products.

The Motley Fool • Aug 7, 2026

NVST vs. ABT: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Products sector have probably already heard of Envista (NVST) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Aug 7, 2026

Abbott Laboratories Lost 16% This Year: One Analyst Sees 35% Gains for the Healthcare Giant

Abbott Laboratories (NYSE:ABT | ABT Price Prediction) currently trades at $105.70, while the Street's consensus price target sits at $118.42, implying roughly 12% of upside.

24/7 Wall Street • Aug 3, 2026

Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Abbott Laboratories maintains a diversified business model spanning diagnostics, medical devices, and nutrition products. Eli Lilly is experiencing rapid growth driven by its dominant presence in the cardiometabolic treatment market.

The Motley Fool • Aug 2, 2026

Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Abbott Laboratories leverages a diversified portfolio across medical devices and diagnostics, bolstered by its recent acquisition of Exact Sciences. Johnson & Johnson maintains superior net margins and massive scale within its pharmaceutical and medical technology divisions.

The Motley Fool • Jul 31, 2026